We claim:

1. Tigogenin pentaglycoside of formula I isolated from aerial parts of *Chlorophytum nimonii*



Formula 1

2. A process for the isolation of a Tigogenin pentaglycoside of formula I from aerial parts of *Chlorophytum nimonii,* which process comprises

(a) soaking material comprising dried and chopped aerial parts of *Chlorophytum nimonii* in a polar solvent at a temperature in the range of 25 to 30°C to obtain an extract;

(b) filtering the extract followed by removal of the polar solvent till dryness under vacuo to obtain the compound of formula 1;

(c) purifying the compound of formula 1



Formula 1

3. A process as claimed in claim 2 wherein the polar solvent used is selected from the group consisting of butanol, methanol, ethanol, water and any mixture thereof.

4. A process as claimed in claim 2 wherein the dried and chopped aerial parts of *Chlorophytum nimonii* is soaked repeated for up to 4 to 5 times in the polar solvent.

5. A process as claimed in claim 2 wherein the soaking is carried on for a period of about 24 hours.

6. A process as claimed in claim 2 wherein the filtrate is concentrated to 300 ml under reduced pressure below 50°C.

7. A process as claimed in claim 2 wherein the polar solvent used is 95% ethanol.

8. A process as claimed in claim 2 wherein the extract obtained at the end of step (ii) is subjected to fractionation into four fractions comprising hexane soluble fraction, n-butanol soluble fraction, chloroform soluble fraction and n-butanol insoluble fraction.

9. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula 1 above and one or more pharmaceutically acceptable additives.

10. A composition as claimed in claim 9 wherein the pharmaceutically effective amount of compound of formula 1 is in the range of 100 to 500 mg/kg of body weight of a patient.

11. Use of compound of formula 1 in the treatment of diabetes and hyperlipidemia.